Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
In the STEP 1 (Semaglutide Treatment Effect in People with obesity) extension study, participants regained about twothirds of the weight they had lost with semaglutide within one year, accompanied by declines in cardiometabolic health [140]
A., & Iasnetsov, V
J Biol Chem 267: 7402-7405, 1992
& Carter, D
Are you feeling stuck in your progress while using GLP-1 medications
Current NHS eligibility criteria for semaglutide 2.4 mg (Wegovy) for weight management, according to NICE TA875, include: Body Mass Index (BMI) 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea) For people from certain high-risk ethnic groups (such as South Asian, Chinese, Black African, or African-Caribbean), lower BMI thresholds apply (typically reduced by 2.5 kg/m) Treatment must be prescribed within specialist weight management services only Treatment is limited to a maximum duration of 2 years Must be used as an adjunct to a reduced-calorie diet and increased physical activity Liraglutide 3 mg (Saxenda) availability varies significantly across NHS regions and is not routinely commissioned in many areas
